Cargando…

eIF4A1 Inhibitor Suppresses Hyperactive mTOR-Associated Tumors by Inducing Necroptosis and G2/M Arrest

Aberrantly activated mechanistic target of rapamycin (mTOR) signaling pathway stimulates translation initiation/protein synthesis and eventually causes tumors. Targeting these processes thus holds potential for treating mTOR-associated diseases. We tested the potential of eFT226, a sequence-selectiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Luyang, Wu, Yuting, Liu, Fangming, Zhang, Hongbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9266907/ https://www.ncbi.nlm.nih.gov/pubmed/35805935 http://dx.doi.org/10.3390/ijms23136932

Ejemplares similares

The Role of mTOR and eIF Signaling in Benign Endometrial Diseases
por: Driva, Tatiana S., et al.
Publicado: (2022)

mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio
por: Alain, Tommy, et al.
Publicado: (2012)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

Hyperactive mTOR and MNK1 phosphorylation of eIF4E confer tamoxifen resistance and estrogen independence through selective mRNA translation reprogramming
por: Geter, Phillip A., et al.
Publicado: (2017)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer
por: Matsumoto, Masaru, et al.
Publicado: (2015)

Metformin blocks MYC protein synthesis in colorectal cancer via mTOR‐4EBP‐eIF4E and MNK1‐eIF4G‐eIF4E signaling
por: Shen, Peng, et al.
Publicado: (2018)

Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy
por: Romagnoli, Alice, et al.
Publicado: (2021)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

In vitro Anti-Hantavirus Activity of Protein Kinase Inhibitor 8G1 Targeting AKT/mTOR/eIF4E Signaling Pathway
por: Li, Zhoupeng, et al.
Publicado: (2022)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy
por: Ramírez-Valle, Francisco, et al.
Publicado: (2008)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

eIF4E3 forms an active eIF4F complex during stresses (eIF4F(S)) targeting mTOR and re-programs the translatome
por: Weiss, Benjamin, et al.
Publicado: (2021)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Temporal and spatial regulation of translation in the mammalian oocyte via the mTOR–eIF4F pathway
por: Susor, Andrej, et al.
Publicado: (2015)

A Critical Role of the mTOR/eIF2α Pathway in Hypoxia-Induced Pulmonary Hypertension
por: Wang, Ai-ping, et al.
Publicado: (2015)

eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway
por: Sun, Liping, et al.
Publicado: (2021)

Predicted mechanisms of resistance to mTOR inhibitors
por: Kurmasheva, R T, et al.
Publicado: (2006)

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Practical considerations for the use of mTOR inhibitors
por: Diekmann, Fritz, et al.
Publicado: (2015)

Deptor: not only a mTOR inhibitor
por: Catena, Valeria, et al.
Publicado: (2017)

Role of mTOR Inhibitors in Kidney Disease
por: Kajiwara, Moto, et al.
Publicado: (2016)

mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
por: Exner, Samantha, et al.
Publicado: (2021)

Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma
por: Demosthenous, Christos, et al.
Publicado: (2015)

Normalizing a hyperactive mTOR initiates muscle growth during obesity
por: Williamson, David L., et al.
Publicado: (2011)

Depdc5 knockdown causes mTOR‐dependent motor hyperactivity in zebrafish
por: de Calbiac, Hortense, et al.
Publicado: (2018)

ubtor Mutation Causes Motor Hyperactivity by Activating mTOR Signaling in Zebrafish
por: Wang, Tiantian, et al.
Publicado: (2021)

Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer
por: Satheesha, Sampoorna, et al.
Publicado: (2011)

mTOR Suppresses Macroautophagy During Striatal Postnatal Development and Is Hyperactive in Mouse Models of Autism Spectrum Disorders
por: Lieberman, Ori J., et al.
Publicado: (2020)

The Androgen Receptor is a negative regulator of eIF4E Phosphorylation at S209: Implications for the use of mTOR inhibitors in advanced prostate cancer
por: D’Abronzo, Leandro S., et al.
Publicado: (2017)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Elevation of EIF4G1 promotes non‐small cell lung cancer progression by activating mTOR signalling
por: Lu, Ying, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uedb99ujopqatg6t97lapfnuqa